ReviewCurrent stem cell research & therapy2025
Unlocking the Potential of Induced Pluripotent Stem Cells in Revolutionizing Cancer Therapy.
Review in Current stem cell research & therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 0 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Induced Pluripotent Stem Cells (iPSCs) are among the top versatile implements of biomedical research. Stem cell science has made strides over the past few years, emerging as a new opportunity to treat cancer, and many such continuous initiatives have been made into clinical trials. As the global mortality rate is too high despite the effectiveness of prevalent cancer therapies, this review explores the potential of iPSC in different aspects of cancer-related areas. The preparation of iPSCs, including their derivation from cancer stem cells, was covered after establishing the intricacy of current cancer treatments. This article highlights the potential of iPSC- based NK cells and dendritic cells for immunotherapy and delves into the role of iPSC-based mesenchymal cells in targeted therapy. The potential of iPSC-derived organoids as a vital tool for disease modeling and drug discovery has been showcased, and the importance of iPSC-based cancer vaccines is also emphasized. The ongoing clinical trials of iPSC-based cancer treatment have also been highlighted. Though much work remains to be done to implicate these iPSC-based therapeutic options from research labs to clinics and hospitals, ongoing studies and clinical/translational follow-ups raise hope for novel cancer therapies employing iPSC technology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.